Opus Genetics (IRD) Change in Account Payables (2020 - 2026)
Opus Genetics (IRD) reported Change in Account Payables of $1.2 million for Q1 2026, up 260.86% year-over-year from $320065.6 in Q1 2025, and up 43.66% quarter-over-quarter from $804000.0 in Q4 2025.
Opus Genetics (IRD) Change in Account Payables (2020 - 2026) Analysis & Trends
Opus Genetics (IRD) has 7 years of Change in Account Payables data on file, last reported at $1.2 million in Q1 2026.
- Change in Account Payables for Q1 2026 came in at $1.2 million, up 260.86% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.9 million (up 559.66% YoY), and the FY2025 annual result was $7000.0, down 96.82% from the prior year.
- Change in Account Payables improved to $1.2 million in Q1 2026 per IRD's latest filing, from $804000.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $1.5 million in Q4 2024 and troughed at -$1.4 million in Q2 2024.
- A 5-year average of $114647.1 and a median of $102000.0 in 2023 frame the typical range for Change in Account Payables.
- The sharpest annual moves came in 2023 and 2024: Change in Account Payables surged 23140.0% in 2023, then slumped 1501.96% in 2024.
- A 5-year view of Change in Account Payables shows it stood at -$390000.0 in 2022, then jumped by 195.64% to $373000.0 in 2023, then jumped by 312.6% to $1.5 million in 2024, then slumped by 47.76% to $804000.0 in 2025, then surged by 43.66% to $1.2 million in 2026.
- Business Quant data shows IRD's Change in Account Payables at $1.2 million in Q1 2026, $804000.0 in Q4 2025, and $906000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -9.42 Mn |
| 10 | Opus Genetics | 355.39 Mn | 295.43 Mn | - | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.16 Mn |
| Mar 31, 2026 | 1.16 Mn |
| Dec 31, 2025 | 804,000.00 |
| Dec 31, 2025 | 804,000.00 |
| Sep 30, 2025 | 906,000.00 |
| Sep 30, 2025 | 906,000.00 |
| Jun 30, 2025 | -985,000.00 |
| Jun 30, 2025 | -985,000.00 |
| Mar 31, 2025 | -718,000.00 |
| Mar 31, 2025 | -718,000.00 |
| Dec 31, 2024 | 1.54 Mn |
| Dec 31, 2024 | 1.54 Mn |
| Sep 30, 2024 | 200,000.00 |
| Sep 30, 2024 | 200,000.00 |
| Jun 30, 2024 | -1.43 Mn |
| Jun 30, 2024 | -1.43 Mn |
| Mar 31, 2024 | -89,000.00 |
| Mar 31, 2024 | -89,000.00 |
| Dec 31, 2023 | 373,000.00 |
| Dec 31, 2023 | 373,000.00 |